I will never forget the first time I did chest compressions on another human being.
You would probably assume that happened in medical school. It did not. It happened in the second year of my Emergency Medicine residency here in the US. I was called to the room of a 58 year old man who had recently been discharged after a myocardial infarction, a 99% occlusion of the left anterior descending artery, the vessel people call the widow maker.
He was short of breath, sweaty, and looked terrible. His oxygen saturation was 88% on room air, his blood pressure was 84/56, and his heart rate was 124. We moved fast and did several things at once. Oxygen, intravenous fluid, more hands in the room. I reached for the ultrasound to look at his heart and lungs and work out what we were actually dealing with. His daughter, who looked to be in her late twenties or early thirties, stood against the wall watching all of it.
I had just found a barely beating heart on the screen when he lost consciousness. A sternal rub did nothing. There was no pulse. I will never forget that first compression, or the sound that came with it, or the look on his daughter's face as my attending walked her out of the room while we called a code for all hands on deck.
He had heart failure from ischemic heart disease. Despite everything we did, he did not survive.
His cholesterol had been high for two decades. Nobody had ever sat down and explained to him what that actually meant. That gap is what this article is written to close.
Start with the part that is genuinely settled
You would never know it from the internet, but the core science here is not a live debate.
LDL is not merely associated with heart disease. It causes it. That is not my personal opinion. It is the conclusion of a consensus panel that assessed the totality of the evidence, including more than 200 prospective cohort studies, Mendelian randomization studies, randomized trials of lipid-lowering therapy, and genetic studies, together covering more than 2 million participants, more than 20 million person-years of follow-up, and over 150,000 cardiovascular events. The relationship is dose-dependent. The more LDL your arteries are exposed to, and the longer they are exposed to it, the higher your risk climbs.¹
This thinking now sits at the front of the current guideline. In March 2026, the American College of Cardiology, the American Heart Association, and nine other societies retired the 2018 blood cholesterol guideline and replaced it with a document retitled the Guideline on the Management of Dyslipidemia. The retitling was deliberate. It signals that risk is carried by atherogenic lipoproteins in general, not by LDL cholesterol alone. The first take-home message of that guideline is to treat dyslipidemia earlier in order to reduce the lifelong risk of prolonged exposure to atherogenic lipoproteins.² In plainer language, lower for longer is better.
And lowering LDL clearly helps. A prospective meta-analysis pooled 14 randomized trials covering 90,056 participants and found that for every 1.0 mmol/L reduction in LDL cholesterol, major vascular events fell by roughly a fifth. That includes heart attacks, strokes, and the need for bypass surgery or stents. All-cause mortality fell by 12% per mmol/L over the same period.³ This is the kind of finding that shows up again and again, across different populations and different drugs. It is about as solid as evidence gets in medicine.
How LDL actually damages an artery
Cholesterol itself is not the villain. It is a type of fat that your body needs for hormone synthesis and for building cell membranes. The problem is logistics. Blood is mostly water, fat and water do not mix, so the body has to package these fatty building blocks into something that can travel.
That packaging is a lipoprotein. There are many types, classified largely by size and structure, and saying they carry cholesterol is not quite accurate. They mostly carry two things, cholesteryl esters and triglycerides. LDL belongs to a family called the beta-lipoproteins, alongside very low-density lipoprotein and intermediate-density lipoprotein. They earned that name because each particle carries a single B100 structural protein on its surface, better known as apolipoprotein B, or ApoB.
That surface protein is what makes the particle atherogenic. There is one ApoB per LDL particle, and the LDL particle carrying it is small enough to slip between the cells lining your artery wall. It does not need high blood sugar to get in. It does not need pre-existing damage. It just needs a gradient, meaning plenty of particles on the outside and few on the inside. Once inside the arterial wall, the ApoB binds irreversibly to proteoglycans, the structural proteins of the innermost layer of the vessel. The trapped particle then oxidizes and sticks in the intima. That triggers an inflammatory response, macrophages arrive to clean up the mess, and over time the whole thing becomes a plaque. The plaque narrows the vessel and fills with cholesterol-rich, calcium-rich, highly thrombogenic material. When it ruptures, you get the heart attack that all of this was trying to prevent.
Hold onto one detail from that paragraph, because it explains most of the confusion that follows. The damage is done by the number of ApoB-carrying particles that get into the wall, not by the amount of cholesterol riding inside them.
Why LDL cholesterol is a surrogate, not the thing itself
When a standard panel reports LDL cholesterol, or LDLc, it is measuring the amount of cholesterol contained within your LDL particles. It is not counting the particles. And it is the particles that do the damage.
Think about a food delivery service. When these companies started, it was clean. One driver, one order. If the amount of cholesterol always tracked the number of particles the way one order tracked one driver, LDLc would be a near-perfect stand-in. But the services got busier. Now one driver carries several orders for several people, and there are bicycles, sedans, and SUVs on the road. Some are big, some are a little dinged up, and those are the oxidized ones. What every vehicle has in common is the company sign on the side, which is the ApoB. When a vehicle crashes, it is the sign and the broken glass that bring out the cleanup crew. So the question worth asking is not how much food is being carried across town. It is how many delivery signs are out there on the road.
This is also why, the next time someone tells you confidently that cholesterol is a myth, you can recognize what is happening. That is not a brave alternative view. It is the deliberate omission of one of the most replicated findings in all of medicine. And I have met the consequences of that advice at 2 a.m. in my emergency department more often than I care to admit.
Your report, line by line
LDL cholesterol
This is the number that matters most, and lower is generally better. But the right target for you depends on your overall risk rather than on a single line on a page. Someone who has already had a heart attack needs a far lower LDL than a healthy 30 year old with no risk factors and no family history. The 2026 guideline brought explicit LDL cholesterol and non-HDL cholesterol treatment goals back, tiered by risk, alongside percentage-reduction targets.²
So when you look at your LDL, the question is never simply whether it is above the line. It is whether it is too high for you, given everything else about you.
HDL cholesterol
Here the story is more interesting than the nickname suggests. HDL got called the good cholesterol because in observational studies, people with higher HDL tended to have less heart disease. That looked like a simple story until the drugs arrived. Agents developed specifically to raise HDL failed to reduce cardiac events despite successfully raising HDL levels.
Genetics tells the same story. A Mendelian randomization study using a genetic variant that raises HDL found that carriers had the higher HDL you would expect, but no corresponding reduction in myocardial infarction risk. When the same method was applied to LDL as a positive control, the genetic effect lined up neatly with the observational one.⁴
High HDL therefore looks more like a marker of good metabolic health than a cause of it. It is a genuinely useful real-world lesson in the difference between correlation and causation, and it is why you should not chase a high HDL number as if it were a score to maximize.
Triglycerides
These are a different kind of fat carried in your blood by lipoproteins, and they are tightly tied to what you eat and drink, to alcohol, to refined carbohydrates, and to how your body handles insulin.
Very high triglycerides can inflame the pancreas, which is an emergency I have treated, usually in the intensive care unit. Moderately high triglycerides are often the first quiet signal that your metabolic health is drifting in the wrong direction, well before anyone gives you a diagnosis of diabetes. The good news is that triglycerides respond to lifestyle change, sometimes dramatically.
Total cholesterol
Honestly, this is the least useful number on the page in isolation, because it lumps everything together. Do not read too much into it on its own.
It becomes useful in context. Take your total cholesterol, subtract your HDL cholesterol, and what is left is your non-HDL cholesterol. That single subtraction gives you a good estimate of your atherogenic cholesterol, it costs nothing extra, and it is genuinely helpful if your panel does not include ApoB.
ApoB
This test is increasingly available, and it gets at the question the standard panel only approximates. ApoB counts the atherogenic particles rather than measuring the cholesterol inside them, so it captures artery-clogging potential more directly.
The 2026 guideline positions ApoB as useful for improving risk assessment and guiding therapy once LDL cholesterol and non-HDL cholesterol goals have already been met, and it highlights three groups in particular: people with elevated triglycerides, people with diabetes, and people who have achieved a low LDL cholesterol of less than 70 mg/dL.² It is worth asking your doctor about, especially if you are making decisions about lipid-lowering therapy or you have already had a cardiac event.
Lipoprotein(a)
Lp(a) is a different beta-lipoprotein that carries its own independent risk. It is largely genetic, it barely moves with lifestyle, and there is currently no approved treatment that lowers it and has been shown to improve outcomes.
The recommendation here has just changed, and it changed in your favor. The 2026 guideline recommends that Lp(a) be measured at least once in adulthood, and it is a risk-enhancing factor at levels of 125 nmol/L or greater, equivalent to 50 mg/dL or greater. It also recommends cascade testing of first-degree relatives when a person's level is high.² Because Lp(a) is genetically determined and stable across your life, once is generally enough. Until we have a treatment that lowers it and improves outcomes, the practical response to a high Lp(a) is to drive your other atherogenic particles lower.
Three claims that sound sophisticated and are not
Now for the arguments you will meet in the comments section, because recognizing the shape of a bad argument is more durable protection than memorizing a rebuttal.
The first is oxidized LDL. The claim is that oxidized particles are more harmful because they provoke the immune system, and the mechanism is real enough as far as it goes. What matters is location. A blood test measures the oxidized LDL circulating in your bloodstream, and those particles get scavenged and cleared by the immune system and by anti-inflammatory compounds in the blood before they end up trapped in the intima. The oxidation that causes plaque happens after the particle is already stuck in the artery wall, which is not what the test is sampling.
The second is particle size. The image of a large, fluffy LDL particle bumping harmlessly around your bloodstream, compared with small dense particles smashing into the artery wall, is a compelling story. LDL particles run roughly 18 to 25 nanometers, and even at the large end they get into the arterial wall perfectly well. Then think about what lipoproteins are for. They are moving cargo. If you have fewer large transports, you need more small ones to move the same load, and every one of those transports carries an ApoB. Your atherogenic particle count goes up. So the size argument, followed all the way through, leads straight back to particle concentration.
The third is the ratio argument, and this is the one that does real harm. The pitch is that low triglycerides and high HDL produce a favorable triglyceride to HDL ratio that is protective, so a sky-high LDL can be waved through. It is often paired with the claim that high LDL simply means the body is repairing itself. We already know that raising HDL with medication does not reduce cardiac events, so a ratio built on HDL cannot carry the weight being placed on it. The ratio also varies by race and by sex, which further limits its use for estimating an individual's risk. If you are using it to decide that your LDL does not matter, you are barking up the wrong tree.
One practical note on fasting
Fasting matters less than it used to for most modern lipid panels, so follow whatever instructions your clinic gives you. Many will still ask you to fast. If your clinic or your emergency department tells you it does not matter, that is accurate. It comes down to plasma residence time. LDL particles stay in the blood for days, compared with hours for some other ApoB-containing particles, so a non-fasting sample is usually adequate.
How Should This Modify Your Practice?
For patients and caregivers
If you have not talked with your doctor about your panel, book the appointment. If you have talked with them and still do not understand what it means for you, pull the report up and go through it line by line while you listen to this episode.
Treat LDL as the number that matters most, and remember that the right target depends on your whole risk picture. Do not chase HDL as a score to maximize. Take your triglycerides seriously as an early metabolic signal, and if they are elevated, move on the foundations: exercise daily, eat more whole plant foods and fiber, and minimize or eliminate alcohol. If your panel does not include ApoB or Lp(a) and you have never had them checked, ask.
The one thing I do not want you to do is sit there and do nothing, especially not because you listened to me or to any other podcast. Bring the report to your physician and ask them to put the whole picture into context so you know what your actual risk is.
And before you go anywhere near a supplement aisle or a Tier 2 optimization, understand that the foundations move these numbers more than most people believe. Diet, exercise, sleep, stress management, and a primary care doctor who tracks your trends over time are the highest-yield tools you have. Triglycerides in particular respond beautifully to them. That primary care relationship is also what turns a number on a page into a plan, which is exactly what my patient in the cold open never got.
For clinicians and trainees
The 2026 dyslipidemia guideline is worth reading in full rather than in summary, because three changes shift day-to-day practice. LDL cholesterol and non-HDL cholesterol treatment goals are back and tiered by risk, ApoB has a defined role once those goals are met, and Lp(a) has moved from a selective test to one recommended at least once in adulthood, with cascade testing of first-degree relatives when elevated.²
Non-HDL cholesterol remains the most underused free number in medicine. It requires no additional assay, it is not affected by fasting status in the way calculated LDL can be, and it captures remnant cholesterol that a calculated LDL will miss when triglycerides are elevated.
On the tests worth declining, NMR particle sizing and oxidized LDL assays do not currently change management in ways that improve outcomes, and ordering them mostly buys the patient a number they cannot act on. A test should serve a clinical question. If you cannot state what you would do differently across the range of possible results, the test is not indicated.
For those of us in emergency medicine, an abnormal lipid panel is not an emergency department problem, and it should not be worked up as one. But the visit itself is a documented handoff opportunity. Naming the finding, telling the patient plainly that it needs primary care follow-up, and writing it into the discharge instructions costs almost nothing and occasionally changes the trajectory. The counterfactual in this case is not dramatic. It is 20 years of a number nobody explained.
About the author
Dr. Adrian Cois, MD is an Emergency Medicine physician and Assistant Professor. He hosts Overheard in the Emergency Room, a podcast and YouTube series translating the evidence behind everyday health decisions into something you can actually use.
Disclosure: Dr. Cois has no financial relationship with any product, company, laboratory, or book mentioned in this episode or article. No affiliate links are used on this site.
Related reading
● Blood Tests, Scans and Surviving a 15-Minute Visit (Season 1, Episode 11), the lab results framework this episode builds on.
● Blood Pressure, Cholesterol and Avoiding the Cath Lab (Season 1, Episode 7), the full cardiovascular risk deep dive.
● S2E2 (17), the Lab Results Explained pillar episode and the hub for this cluster.
● Food, NAFLD and the 80/20 Plate (Season 1, Episode 2), on the dietary foundations that move triglycerides.
● Your Ultimate Supplement Guide (Season 1, Episode 14), before anyone sells you a cholesterol supplement.
References
AMA style. All four verified against PubMed on August 30, 2026.
1. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-2472. doi:10.1093/eurheartj/ehx144
2. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;153(17):e1154-e1276. doi:10.1161/CIR.0000000000001423
3. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-1278. doi:10.1016/S0140-6736(05)67394-1
4. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380(9841):572-580. doi:10.1016/S0140-6736(12)60312-2
